A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation.
about
Therapeutic targeting of liver inflammation and fibrosis by nanomedicineAdvances in Integrative Nanomedicine for Improving Infectious Disease Treatment in Public HealthEffectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H/HeN Mice ModelLiver fibrosis and mechanisms of the protective action of medicinal plants targeting inflammation and the immune response.Nanotechnology applications for the therapy of liver fibrosis.Low-level laser therapy ameliorates CCl4-induced liver cirrhosis in rats.Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in ratsCurcumin loaded NIPAAM/VP/PEG-A nanoparticles: physicochemical and chemopreventive properties.Functional characterization of a competitive peptide antagonist of p65 in human macrophage-like cells suggests therapeutic potential for chronic inflammation.Semi-quantitative monitoring of confluence of adherent mesenchymal stromal cells on calcium-phosphate granules by using widefield microscopy images.Therapeutic Applications of Curcumin NanoformulationsA composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.Efficacy of gold nanoparticles against isoproterenol induced acute myocardial infarction in adult male albino rats.Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategiesIntraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populCellular distribution of injected PLGA-nanoparticles in the liver.Inhibition of caspase-9 aggravates acute liver injury through suppression of cytoprotective autophagy.Curcumin and liver disease.Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapiesStrategies to prevent and reverse liver fibrosis in humans and laboratory animals.A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives.PNIPAAm-MAA nanoparticles as delivery vehicles for curcumin against MCF-7 breast cancer cells.Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin.Pharmaceutical differences between block copolymer self-assembled and cross-linked nanoassemblies as carriers for tunable drug release.Comparative Neuroprotective Effects of Dietary Curcumin and Solid Lipid Curcumin Particles in Cultured Mouse Neuroblastoma Cells after Exposure to Aβ42Diethylcarbamazine reduces chronic inflammation and fibrosis in carbon tetrachloride- (CCl₄-) induced liver injury in mice.Effect of medicated serum of Curcumae Radix extract on mRNA expression of TIMP-1, MMPs-13 and aI-collagen of HSC-T6 cell.Silymarin decreases connective tissue growth factor to improve liver fibrosis in rats treated with carbon tetrachloride.Curcumin attenuates high glucose-induced inflammatory injury through the reactive oxygen species-phosphoinositide 3-kinase/protein kinase B-nuclear factor-κB signaling pathway in rat thoracic aorta endothelial cells.Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis.Attenuation of carbon tetrachloride-induced hepatic injury with curcumin-loaded solid lipid nanoparticles.
P2860
Q27000074-E6A51C1A-FBDB-4153-8AB8-7866D9CC914DQ28384520-A8716E9A-950D-448C-851E-D2F95A80D53DQ28551990-A66458E6-9756-4811-A01A-1551BADB3493Q30374500-70F41438-031E-4AA3-8AC0-0734ACC00606Q33780124-CE46F233-6A8F-43F5-AFF6-068846A0EC68Q34349861-576F5ED8-D740-49C1-85B1-CA570305A22EQ34414756-5628BE85-CC61-477E-8F21-DDF6A83F61A8Q34658997-74F9A15D-9F72-4EB7-8C6B-F2C8344945DDQ34672342-22221FF9-1C47-4726-A31A-A3029992D597Q35174407-69A8219B-6B4B-4A52-BD4E-EE43BEABF5B6Q36232513-E8BCFE2C-C674-4C47-BF54-B6EB32247390Q36234061-FEA7E2C9-C88C-48C8-9D36-B1F84546717CQ36301960-48EF46FD-7AF1-42A3-8D1C-FE72871CEC66Q36561567-295C7260-4C11-4B98-B610-AF18A0A67D00Q36647007-14A8CA2C-C23F-48F1-9B93-CE8DF9C6B085Q36957725-F011F8F2-DE40-49B0-AF31-ED520E2D90A5Q37223485-FFDA2FCB-F5B8-463F-B626-D27F910B7E19Q38072883-84D007E2-538A-4535-A592-2A19566DC0F4Q38073028-E01897A7-F6B7-4885-BACA-9617A3E7D31AQ38473640-0DF4DBF8-F415-48B3-BBBF-610E762C6954Q38588143-F8448775-7DE4-4FCB-8C55-074709353B4EQ38893647-42FA890B-96AB-4601-BFF1-4D057968B877Q39046987-CCD14349-9114-4CA3-8095-51182D6B6214Q39262135-29100F04-5888-4962-8CED-D0267EEB558EQ41785626-9C7658C5-AA5F-48B2-A68F-FC2CBC9FE3D2Q41889295-E0C20F06-1C58-4B52-ABCB-604AAEA46EA9Q42240679-87D99CCF-0023-4E28-B2FD-47CCB868ADDDQ43542076-A4D8605D-8445-4D5C-B2A7-109525B79DC5Q46272793-B50DCAF6-5710-4C10-BD18-61397312747AQ47274086-64B9789E-DAC1-42B1-8298-B8B03D170A8BQ48345993-C9DB0CDA-476C-4E7E-ACB0-FA531B77C619
P2860
A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A polymeric nanoparticle formu ...... and stellate cell activation.
@ast
A polymeric nanoparticle formu ...... and stellate cell activation.
@en
type
label
A polymeric nanoparticle formu ...... and stellate cell activation.
@ast
A polymeric nanoparticle formu ...... and stellate cell activation.
@en
prefLabel
A polymeric nanoparticle formu ...... and stellate cell activation.
@ast
A polymeric nanoparticle formu ...... and stellate cell activation.
@en
P2093
P2860
P1476
A polymeric nanoparticle formu ...... s and stellate cell activation
@en
P2093
Amarnath Maitra
Anirban Maitra
Balmiki Ray
Debomoy Lahiri
Masamichi Mizuma
Mehtab A Khan
Mena Bekhit
Michelle A Rudek
P2860
P2888
P304
P356
10.1038/LABINVEST.2011.86
P50
P577
2011-06-20T00:00:00Z